Evaluation of efficacy and safety of terazosin in patients with benign prostatic hyperplasia with lower urinary tract symptoms

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0005278

Enrollment

174

Registered

2020-08-04

Start date

2020-09-01

Completion date

Unknown

Last updated

2020-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Terazosin 2mg QD group Terazosin 2mg BID group Terazosin 5mg QD group

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) Male over 40 years old (2) A person with an IPSS total score of 8 or higher (3) Those whose maximum urine velocity (Qmax) is less than 10mL/s (4) Those who have a single void volume of 150 mL or more (5) A person who consented to participate in this study by handwritten signature

Exclusion criteria

Exclusion criteria: (1) People who are hypersensitive to Alpha-blocker drugs (2) People with bladder neck stenosis and urinary tract stenosis (3) Those with renal dysfunction (creatinine concentration in serum>2.0mg/dL) (4) People who have a severe liver disorder or have a history (5) People with severe cardiovascular disease (6) People with severe hypotension (7) Other research directors judge that it is inappropriate to participate in this research

Design outcomes

Primary

Measure	Time frame
Change in IPSS(International Prostate Symptom Score) total score	—

Secondary

Measure	Time frame
Change in OABSS(Overactive Bladder Symptom Score) total score;Change in Qmax and Qave;IPSS (International Prostate Symptom Score) Total change rate(~10%, 10-30%, 30%~);Change in IPSS-QoL(International Prostate Symptom Score-Quality of life)	—

Countries

Korea, Republic of

Contacts

Public ContactTae Wook Kang

Yonsei University, Wonju Severance Christian Hospital

Outcome results